Embracing the Importance of HFrEF and HFpEF GDMT

Boehringer Ingelheim and Lilly Cardiology

M. Budoff

Overcoming Barriers to HFrEF GDMT Use

Boehringer Ingelheim and Lilly Cardiology

N. Singh

The Shift to Rapid Sequencing to Improve Patient Outcomes in HFrEF

Boehringer Ingelheim and Lilly Cardiology

K. Watson

Timely Implementation of HFrEF GDMT

Boehringer Ingelheim

N. Singh

Optimal Medical Therapy for Patients with HFrEF - Four Pharmacologic…

Boehringer Ingelheim and Lilly Cardiology

N. Singh, N. Lepor, K. Watson, M. Budoff, R. Chilton

Heart Failure Prevention

UCLA Health

K. Watson

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Pharmacologic Options for Managing Obesity in Patients with Heart Fa…

UCLA Health

V. Surampudi

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

ECG Interpretation: Everything You Need to Know to Understand and In…

Houston Methodist DeBakey Heart and Vascular Center

A. Dave

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Diabetes: Matters of the Heart

Scripps Health

M. Wilkinson

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim